Application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses

A dihydroflavonol and ethoxy technology, applied in the field of medicine, can solve the problems of no reported anti-HBV activity, etc., and achieve the effects of clear industrialization prospects, large-scale production of energy saving and emission reduction, and convenient synthesis
CN101822664BInactive Publication Date: 2012-05-23DALI UNIV
11 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
DALI UNIV
Publication Date
2012-05-23
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of20 microgram / milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the technical field of medicine, specifically, the present invention relates to a kind of B ring ethoxy substituted dihydroflavonol or its pharmaceutically acceptable salt is used for preparing and reducing hepatitis B virus surface antigen HBsAg and hepatitis B e antigen HBeAg, inhibiting HBV DNA Use of medicines for replicating or treating hepatitis B virus infection. This flavonoid lignan has definite activity of inhibiting HBsAg and HBeAg, and its intensity of removing HBsAg and HBeAg is respectively 99.8% and 48.5% under the concentration of 20 micrograms / milliliter, is positive contrast drug (10000 unit / milliliter α-interference 6.2 times and 2.7 times that of interferon; more importantly: at this concentration, it shows a 64.7% inhibition rate to HBV DNA, and its activity is 1.7 times that of interferon. The above pharmacodynamic results show that the B ring ethoxy substituted dihydroflavonol or its pharmaceutical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More